➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Boehringer Ingelheim
AstraZeneca
Moodys
Dow

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 10,413,607

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,413,607
Title:Antibody specifically binding to ErbB3 and use thereof
Abstract: An antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof, and use thereof, are provided. The antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof may be effectively used to prevent or treat a disease related to activation or overexpression of ErbB3 protein.
Inventor(s): Bae; Dong Goo (Gyeonggi-do, KR), Kim; Mi Young (Seoul, KR), Hur; Young Mi (Gyeonggi-do, KR), Hong; Mi Rim (Seoul, KR)
Assignee: ISU ABXIS CO., LTD. (Gyeonggi-Do, KR)
Application Number:15/563,227
Patent Claims:see list of patent claims

Details for Patent 10,413,607

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ISU ABXIS CO., LTD. (Gyeonggi-Do, KR) 2035-12-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Dow
Medtronic
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.